Reuters: Regulatory News: Eli Lilly's lymphoma drug fails in late-stage trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Eli Lilly's lymphoma drug fails in late-stage trial May 10th 2013, 12:24 Fri May 10, 2013 8:24am EDT May 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients' disease-free survival. The drug, enzastaurin, was being tested in lymphoma patients who were at high risk of relapse following a chemotherapy treatment. Lymphoma is a cancer of the lymphatic system. The decision to stop the drug's development will result in a second-quarter charge of about $30 million but the company's 2013 forecast remained unchanged, Lilly said in a statement.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions